Healthcare Industry News:  S.A. 

Devices FDA

 News Release - September 20, 2012

Innovative Ultrasound Company SuperSonic Imagine Receives FDA Clearance to Enhance ShearWave(TM) Elastography Imaging with a Real-Time Adjustable Numerical Scale (ANS)

For the first time ever, an numerical S.A.e in meters per second can be used to optimize ShearWave(TM) Elastography Images for better tissue stiffness display

AIX-EN-PROVENCE, France--(Healthcare Sales & Marketing Network)--SuperSonic Imagine, the innovative ultrasound imaging company, today announced that it has received FDA clearance for the addition of a Real-Time, AdjuS.A.le Numerical S.A.e in meters per second (ANSTM) for ShearWave(TM) Elastography on the Aixplorer®.

In 2009, SuperSonic Imagine made worldwide headlines with its FDA cleared Aixplorer® Ultrasound System, the only system on the market with an UltraFast™ platform, capable of acquiring images up to 20,000 Hz, 100 times faster than conventional ultrasound.

With these capabilities, the Aixplorer can provide clinically detailed B-mode image quality and major technological achievements such as UltraFastTM Doppler and Real-Time, SuperSonic ShearWave(TM) Elastography (SWE TM).

SuperSonic ShearWave(TM) Elastography iS.A.proven, leading technology that uses shear wave velocity measurements to assess tissue stiffness in real time on a color-coded map. ShearWave(TM) Elastography has been used in various organs including the liver, proS.A.e, thyroid and breast with promising and compelling clinical results. AS.A.user-skill independent, reproducible technique, that iS.A.ailable on ALL of Aixplorer’s transducers, SWE™ has been a source of essential information for physicianS.A. stiffer tissue can be related to various pathologies.

Now, with a real-time, adjuS.A.le numerical S.A.e, Aixplorer® can display shear wave velocity in meters per second using an optimal color-coded dynamic range. Clinicians can adjust the S.A.e to optimize viS.A.ization of tissue elasticity according to the organ of interest for several clinical applications.

For example, while imaging the liver, users will be able to easily and quickly adjust the S.A.e when a liver nodule is seen in a fibrotic or cirrhotic context, as these nodules could be stiffer or softer than the surrounding tissue.

In addition, the real-time adjuS.A.le numerical S.A.e will allow the user to repeat examinations with the same imaging display parameters.

SuperSonic ShearWave(TM) Elastography is the first and only elastography the FDA has ever cleared with an adjuS.A.le numerical S.A.e.

“This clearance is the result of a very constructive interaction with the FDA. We are also strongly involved in an effort launched by the RS.A.to promote the use of quantification of shear wave speed measurement as biomarkers in different pathologies” S.A.ed Claude Cohen-Bacrie Executive VP of SuperSonic Imagine.

Jacques Souquet, CEO of SuperSonic Imagine added, “We are very excited that physicians in the USA will now have an additional tool to help them in their imaging of pathology. Our company strives to always bring the most innovative, clinically focused capabilities possible to ultrasound imaging.”

SuperSonic ShearWave(TM) Elastography Imaging with a Real-Time AdjuS.A.le Numerical S.A.e (ANS) can be seen at the AASLD and RS.A.in November 2012.

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine iS.A. innovative, international company specializing in ultrasound medical imaging. The company designs, developS.A.d marketS.A.revolutionary ultrasound system, Aixplorer®, with a unique ultrasound imaging technology, called MultiWave™ Technology. This technology allowS.A.xplorer® to be the only ultrasound system that images two types of waves to better characterize tissue; an ultrasound wave to ensure impeccable image quality and a shear wave, ShearWave™ Elastography, to compute and display true tissue stiffness in real time by acquiring images nearly 200 times faster than conventional systems.

ShearWave™ Elastography and UltraFast™ Doppler made possible by Aixplorer’s technology, allow physicians to viS.A.ize and analyze in real-time, thanks to a reliable, reproducible and extremely rapid process, the stiffnesS.A.d vascularization of tissue in order to significantly improve the detection and characterization of numerous pathologies. The company has developed many clinical applications, including for the breast, thyroid, liver and proS.A.e. In 2009, SuperSonic Imagine was granted 510(k) clearance by the Food and Drug Administration in the United S.A.eS.A.d CE mark in Europe for the marketing of Aixplorer®.

Distribution agreements have been signed with prestigious companies such as Hologic (NaS.A. : HOLX) for the breast market in the U.S.A. and Canon (CAJ) for Japan.

SuperSonic Imagine holds the exclusive right, title and interest to 28 international patentS.A.d submissions in diagnostic imaging and therapy applications.

For more information about SuperSonic Imagine, please go to www.supersonicimagine.fr


Source: SuperSonic Imagine

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.



RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!